Currently, PD-L1 expression on tumor cells assessed by immunohistochemistry is the only approved diagnosis biomarker for immunotherapy in patients with NSCLC and has been shown to be related with the efficacy of immune checkpoint inhibitors (ICIs) in NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.